Navigation Links
Rentschler Biotechnologie Extends Capacities for Mammalian Cell Culture Manufacturing

Laupheim, Germany – June 20, 2008 / b3c newswire /  - Rentschler Biotechnologie, a leading full-service contract manufacturing organization (CMO) for the development and production of biopharmaceuticals in mammalian cells, started operation of a 2,500 L multi-process production suite. Hence, Rentschler Biotechnologie now has nine stand-alone GMP suites with volumes of 30, 250, 500 and 2,500 liters, allowing the production of material for clinical trials and for market supply.

The modern, state-of-the-art 2,500 L bioreactor is designed such that batch, fed-batch, or perfusion cell culture processes can be run. Protein purification is performed in two suites for pre- and post-virus inactivation, respectively.

Using its modern GMP production suites, Rentschler Biotechnologie offers its customers comprehensive services “from gene to drug product”. It is able to develop tailored solutions for each customer through all phases of development and production. Due to its “preferred partnership” agreement with Boehringer Ingelheim, customers requiring higher production capacities than that offered by Rentschler, receive easy access to Boehringer’s large-scale bioreactor volumes of up to 15,000 L.

The global market for biopharmaceutical products is growing constantly and rapidly. As a consequence, since 2002, Rentschler Biotechnologie has invested more than 70 million Euros to enhance its production capacities. Rentschler has thus consolidated its position as a contract manufacturing organization (CMO) for the production of biopharmaceuticals and is now one of three leading European CMOs in this market segment. Since 2001 the number of employees has grown three-fold up to the present 350. 

About Rentschler Biotechnologie –
Rentschler Biotechnologie GmbH is part of the privately held Rentschler Group based in Laupheim, Germany. As an international full-service contract manufacturer with a highly skilled staff of 350, Rentschler Biotechnologie has substantial long-term experience in the development, production and approval of cell culture-derived biopharmaceuticals in compliance with international GMP standards. Regulatory advice and fill & finish are part of the company's service range.

Dr. Wieland Wolf
Dr. Rentschler Holding GmbH & Co. KG
Phone: +49 (0)7392-701-0

Media contact:
Friederike Braun
Phone: +49 (0)7392 701–555


Related biology technology :

1. Rentschler Biotechnologie Announces Cooperation with Boehringer Ingelheim
2. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
3. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
4. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
5. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
6. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Completion of $2,277,000 Equity Financing
7. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Appointment of Mark C. Mirken as its President and Chief Operating Officer
8. Amyris Biotechnologies Announces $70 Million Series B Round
9. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
10. Epeius Biotechnologies Leads With Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference in Boston MA
11. Maven Biotechnologies, LLC to Present at BIOCOM Investor Conference
Post Your Comments:
(Date:11/24/2015)... LUMPUR, Malaysia , Nov. 24, 2015 /PRNewswire/ ... global contract research organisation (CRO) market. The trend ... result in lower margins but higher volume share ... increased capacity and scale, however, margins in the ... Research Organisation (CRO) Market ( ), ...
(Date:11/24/2015)... 2015 /CNW/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended September 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... said Andrew Rae , President & CEO ... not only value enriching for this clinical program, ...
(Date:11/24/2015)... 2015  Clintrax Global, Inc., a worldwide provider of clinical research ... announced that the company has set a new quarterly earnings record ... quarter growth posted for Q3 of 2014 to Q3 of 2015. ... Mexico , with the establishment of an Asia-Pacific ... United Kingdom and Mexico ...
(Date:11/24/2015)... Massachusetts , November 24, 2015 SHPG ... will participate in the Piper Jaffray 27 th Annual Healthcare ... Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ... , Chief Financial Officer, will participate in the Piper Jaffray 27 ... , NY on Tuesday, December 1, 2015, at 8:30 a.m. ...
Breaking Biology Technology:
(Date:11/17/2015)... Mass. , Nov. 17, 2015 Pressure ... leader in the development and sale of broadly enabling, ... worldwide life sciences industry, today announced it has received ... its $5 million Private Placement (the "Offering"), increasing the ... $4,025,000.  One or more additional closings are expected in ...
(Date:11/11/2015)... 11, 2015   MedNet Solutions , an innovative SaaS-based ... research, is pleased to announce that it will be a ... event, to be held November 17-19 in ... live demonstrations of iMedNet , MedNet,s easy-to-use, ... iMedNet has been able to deliver time and cost ...
(Date:11/4/2015)... , November 4, 2015 ... new market report published by Transparency Market Research "Home Security ... Trends and Forecast 2015 - 2022", the global home security ... 30.3 bn by 2022. The market is estimated to ... period from 2015 to 2022. Rising security needs among ...
Breaking Biology News(10 mins):